Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
0.4719
Dollar change
-0.0581
Percentage change
-10.96
%
Index- P/E- EPS (ttm)-0.51 Insider Own33.38% Shs Outstand66.44M Perf Week-6.57%
Market Cap43.62M Forward P/E- EPS next Y-0.05 Insider Trans0.00% Shs Float61.58M Perf Month54.82%
Income-36.06M PEG- EPS next Q-0.05 Inst Own4.35% Short Float6.03% Perf Quarter-0.44%
Sales0.00M P/S- EPS this Y35.00% Inst Trans10.73% Short Ratio2.53 Perf Half Y88.38%
Book/sh-0.07 P/B- EPS next Y80.77% ROA-190.11% Short Interest3.71M Perf Year-34.91%
Cash/sh0.10 P/C4.90 EPS next 5Y- ROE-682.61% 52W Range0.22 - 1.20 Perf YTD2.59%
Dividend Est.- P/FCF- EPS past 5Y-120.49% ROI- 52W High-60.68% Beta1.04
Dividend TTM- Quick Ratio0.68 Sales past 5Y0.00% Gross Margin- 52W Low113.53% ATR (14)0.08
Dividend Ex-Date- Current Ratio0.68 EPS Y/Y TTM47.75% Oper. Margin0.00% RSI (14)47.67 Volatility14.94% 17.92%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price3.17
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q45.87% Payout- Rel Volume1.73 Prev Close0.53
Sales Surprise- EPS Surprise28.57% Sales Q/Q- EarningsMar 28 AMC Avg Volume1.47M Price0.47
SMA20-10.35% SMA501.70% SMA20023.36% Trades Volume2,533,695 Change-10.96%
Mar-28-24 10:53PM
08:03AM
08:00AM
Mar-26-24 04:03PM
Mar-25-24 08:30AM
04:02PM Loading…
Mar-21-24 04:02PM
01:57PM
Mar-18-24 08:30AM
Mar-12-24 07:49AM
Mar-11-24 08:30AM
Mar-04-24 08:30AM
Mar-01-24 08:30AM
Feb-27-24 10:49AM
08:54AM
08:31AM
04:01PM Loading…
Feb-26-24 04:01PM
08:30AM
Feb-20-24 08:30AM
Feb-12-24 08:30AM
Feb-09-24 08:30AM
Feb-05-24 06:48AM
Jan-22-24 06:48AM
Jan-17-24 06:48AM
Jan-16-24 06:48AM
Jan-02-24 08:45AM
06:48AM
Dec-27-23 06:48AM
Dec-19-23 08:15AM
Dec-18-23 06:48AM
Dec-13-23 04:02PM
06:48AM Loading…
Dec-11-23 06:48AM
Nov-27-23 04:01PM
Nov-16-23 02:07PM
09:32AM
Nov-13-23 06:39PM
Nov-07-23 06:48AM
Nov-06-23 06:48AM
Oct-31-23 06:48AM
Oct-26-23 06:48AM
Oct-12-23 06:48AM
Oct-05-23 06:48AM
Oct-02-23 06:48AM
Sep-21-23 09:35AM
Sep-20-23 06:47AM
Sep-19-23 09:00AM
Sep-18-23 06:46AM
Sep-15-23 06:46AM
Sep-14-23 04:01PM
Sep-07-23 06:47AM
Sep-06-23 10:55AM
Aug-30-23 06:47AM
Aug-29-23 06:54AM
Aug-14-23 04:01PM
Aug-07-23 06:47AM
06:47AM
Jun-20-23 04:01PM
Jun-09-23 08:45AM
Jun-06-23 12:20PM
Jun-02-23 02:19PM
May-16-23 06:47AM
May-10-23 04:05PM
Apr-27-23 04:01PM
Mar-30-23 04:01PM
Mar-27-23 06:47AM
Mar-17-23 06:47AM
Mar-09-23 06:47AM
Feb-22-23 06:47AM
Feb-13-23 06:47AM
Feb-02-23 06:47AM
Jan-19-23 06:47AM
Jan-05-23 06:47AM
Jan-03-23 06:47AM
Dec-20-22 01:30AM
Dec-05-22 06:47AM
Dec-02-22 06:47AM
Nov-14-22 06:47AM
01:30AM
Nov-10-22 06:47AM
Nov-09-22 06:47AM
Nov-07-22 06:47AM
Sep-08-22 06:40AM
Aug-22-22 12:09PM
06:00AM
Aug-15-22 06:50AM
Aug-10-22 12:41PM
Jul-13-22 07:15AM
Jul-01-22 07:23AM
Jun-23-22 07:45AM
Jun-22-22 06:33PM
Jun-10-22 10:47PM
Jun-07-22 08:02PM
May-26-22 12:03AM
May-19-22 07:20AM
May-16-22 07:12AM
May-12-22 08:17AM
May-10-22 08:11AM
Apr-21-22 08:48AM
Apr-08-22 08:57AM
Mar-31-22 08:17AM
08:17AM
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hurvitz ChaimDirectorAug 30 '23Buy0.2970,00020,125570,000Sep 11 09:15 AM
Gorovitz AaronDirectorAug 30 '23Buy0.3235,00011,196105,000Sep 11 09:19 AM
Javitt Jonathan CChief ScientistAug 23 '23Buy0.33100,00033,000446,332Aug 24 12:14 PM
Javitt Jonathan CChief ScientistAug 22 '23Buy0.32200,00064,400346,332Aug 23 09:24 AM